Drugs A-Z Is my price fair? Price changes Drug markups Drug shortages Recalls Medicare prices Upcoming generics What people paid Guides Share what you paid
Theme

Updated daily

Drug recalls

Every FDA drug recall since 2004 - 18,109 enforcement reports, newest first, with what was recalled, why, the lots and the company. Class I is the most serious.

Class IIITerminatedNov 16, 2016Kamedis BIO-HERBAL DANDRUFF CARE THERAPEUTIC 2-STEP DANDRUFF CARE SYSTEM - Kamedis Bio-Herbal Dandruff Care...Subpotent Drug: Out of Specification assay values on stability for the active ingredient, zinc pyrithione.Taro Pharmaceuticals U.S.A., Inc. · D-0134-2017Class IITerminatedNov 16, 2016Transderm ScopDefective Delivery System; reports of damaged product that may alter the predicted release of scopolamine following transdermal application.Sandoz Inc · D-0133-2017Class IIITerminatedNov 16, 2016Estradiol 12.5 mg PelletSuperpotent and Subpotent drugsWells Pharmacy Network, LLC · D-0132-2017Class IITerminatedNov 16, 2016Testosterone 200 mg/Anastrazole 20mg PelletSuperpotent and Subpotent drugsWells Pharmacy Network, LLC · D-0131-2017Class IIITerminatedNov 16, 2016Estradiol 3 mg PelletSuperpotent and Subpotent drugsWells Pharmacy Network, LLC · D-0130-2017Class IIITerminatedNov 16, 2016Testosterone 12.5 mg PelletSuperpotent and Subpotent drugsWells Pharmacy Network, LLC · D-0129-2017Class IITerminatedNov 16, 2016Testosterone 60 mg/Anastrazole 4 mg PelletSuperpotent and Subpotent drugsWells Pharmacy Network, LLC · D-0128-2017Class IIITerminatedNov 16, 2016Testosterone CholesterolSuperpotent and Subpotent drugsWells Pharmacy Network, LLC · D-0127-2017Class IITerminatedNov 16, 2016Testosterone 200 mg/Anastrozole 9 mg PelletSuperpotent and Subpotent drugsWells Pharmacy Network, LLC · D-0126-2017Class IITerminatedNov 9, 2016Succinylcholine ChlorideLack of Assurance of Sterility: A portion of the batch quantity was compounded outside of the firm's process media validation.Pharmedium Services, LLC · D-0125-2017Class IITerminatedNov 9, 2016Sodium Chloride Ophthalmic SolutionSubpotent Drug: concentration of product is less than labeled amount.Akorn Inc · D-0124-2017Class IIITerminatedNov 9, 2016Gildess 24 FE 1.5/30Subpotent Drug; Ethinyl EstradiolPar Pharmaceutical, Inc. · D-0123-2017Class IIITerminatedNov 9, 2016Gildess FE 1.5/30Subpotent Drug; Ethinyl EstradiolPar Pharmaceutical, Inc. · D-0122-2017Class IIITerminatedNov 9, 2016Gildess FE 1/20Subpotent Drug; Ethinyl EstradiolPar Pharmaceutical, Inc. · D-0121-2017Class IIITerminatedNov 9, 2016Gildess 1/20Subpotent Drug; Ethinyl EstradiolPar Pharmaceutical, Inc. · D-0120-2017Class IIITerminatedNov 9, 2016Gildess 1.5/30Subpotent Drug; Ethinyl EstradiolPar Pharmaceutical, Inc. · D-0119-2017Class IIITerminatedNov 9, 2016Ramipril CapsulesLabeling: Incorrect or Missing Lot And/or Exp Date: Bottles labeled with the incorrect expiration date of 03/18 rather than 09/17.Actavis Laboratories, FL, Inc. · D-0118-2017Class IITerminatedNov 9, 2016Desoximetasone Cream USPFailed Stability Specifications: The subject lots exhibited OOS results for Homogeneity test (Moderate separation).Taro Pharmaceuticals, Inc. · D-0117-2017Class IITerminatedNov 9, 2016Desoximetasone Cream USPFailed Stability Specifications: The subject lots exhibited OOS results for Homogeneity test (Moderate separation).Taro Pharmaceuticals, Inc. · D-0116-2017Class IIITerminatedNov 2, 2016InvokametLabeling: Incorrect or Missing Package Insert - Xarelto prescribing information outserts may be affixed to the exterior of Invokamet bottles in place of the Invokamet...Janssen Ortho L.L.C. · D-0115-2017Class IITerminatedNov 2, 2016DIPYRIDAMOLE Tablets USPPresence of foreign tablets/capsules: 50 mg Persantine tablets were found in a 75 mg Persantine 100-count bottle and 50 mg Persantine tablet was found in a 100 count...Boehringer Ingelheim Pharmaceuticals, Inc. · D-0114-2017Class IITerminatedNov 2, 2016PersantinePresence of foreign tablets/capsules: 50 mg Persantine tablets were found in a 75 mg Persantine 100-count bottle and 50 mg Persantine tablet was found in a 100 count...Boehringer Ingelheim Pharmaceuticals, Inc. · D-0113-2017Class IITerminatedOct 26, 2016Trokendi XRSuperpotent Drug: Failure of assay specifications in the capsule.Supernus Pharmaceuticals, Inc. · D-0112-2017Class IIITerminatedOct 26, 2016PARICALCITOL CapsulesFailed Impurities/Degradation Specifications: out of specification test results for impurities during stability testing.Teva Pharmaceuticals USA · D-0111-2017Class IIITerminatedOct 26, 2016PARICALCITOL CapsulesFailed Impurities/Degradation Specifications: out of specification test results for impurities during stability testing.Teva Pharmaceuticals USA · D-0110-2017Class IIITerminatedOct 26, 2016PARICALCITOL CapsulesFailed Impurities/Degradation Specifications: out of specification test results for impurities during stability testing.Teva Pharmaceuticals USA · D-0109-2017Class IITerminatedOct 26, 2016Dream Body Advanced 400 mg 30 capsules in brown foil packetsMarketed without an approved NDA/ANDA: Undeclared sibutramine.Dream Body Weight Loss · D-0108-2017Class IITerminatedOct 26, 2016Dream Body 450 mg 30 capsules in a plastic screw on top bottleMarketed without an approved NDA/ANDA: Undeclared sibutramine.Dream Body Weight Loss · D-0107-2017Class IITerminatedOct 26, 2016Dream Body Extreme Gold 800 mg 30 capsules in a plastic screw on top bottleMarketed without an approved NDA/ANDA: Undeclared sibutramine.Dream Body Weight Loss · D-0106-2017Class ITerminatedOct 26, 2016CetylevDefective Container: Incomplete seal on blister packaging, leading to tablet swelling and enlarging due to effervescence process beginning as oxygen and moisture enter...Arbor Pharmaceuticals Inc. · D-0105-2017Class ITerminatedOct 26, 2016Super Samurai-XMarketed without an approved NDA/ANDA: FDA sample analyses revealed the presence of undeclared sildenafil and/or its analogs in products marketed as dietary supplementsSOS Telecom Inc. · D-0104-2017Class ITerminatedOct 26, 2016Ginseng Power-XMarketed without an approved NDA/ANDA: FDA sample analyses revealed the presence of undeclared sildenafil and/or its analogs in products marketed as dietary supplementsSOS Telecom Inc. · D-0103-2017Class ITerminatedOct 26, 2016Ninja-X, 4200 mgMarketed without an approved NDA/ANDA: FDA sample analyses revealed the presence of undeclared sildenafil and/or its analogs in products marketed as dietary supplementsSOS Telecom Inc. · D-0102-2017Class ITerminatedOct 26, 2016Tiger-X, 1200 mgMarketed without an approved NDA/ANDA: FDA sample analyses revealed the presence of undeclared sildenafil and/or its analogs in products marketed as dietary supplementsSOS Telecom Inc. · D-0101-2017Class IITerminatedOct 19, 2016TAZORACFailed Content Uniformity SpecificationsAllergan Sales, LLC · D-0100-2017Class IITerminatedOct 19, 2016TAZORACFailed Content Uniformity SpecificationsAllergan Sales, LLC · D-0099-2017Class IIITerminatedOct 19, 2016ZENATANEFailed Dissolution SpecificationsDr. Reddy's Laboratories, Inc. · D-0098-2017Class IITerminatedOct 19, 2016Marcaine 0.5%Lack of Assurance of Sterility and Subpotent Drug: defect in glass vial prevented stopper from forming a seal allowing water to ingress and dilute the product causing it...Hospira Inc., A Pfizer Company · D-0097-2017Class IITerminatedOct 19, 2016Marcaine 0.25%Lack of Assurance of Sterility and Subpotent Drug: defect in glass vial prevented stopper from forming a seal allowing water to ingress and dilute the product causing it...Hospira Inc., A Pfizer Company · D-0096-2017Class IIITerminatedOct 19, 2016mitoXANTRONE Injection USPFailed Impurities/Degradation Specifications: potential failure to meet the specification for Impurity D throughout shelf-life.Teva Pharmaceuticals USA · D-0095-2017

Help the next person

Know what your pharmacy pays.

Every price you share shows someone else what's fair - and which pharmacies charge the least. It takes 30 seconds and it's anonymous.